(Bloomberg) — Biogen Inc. shed more than $3 billion in market value in the past two trading sessions as a patent review of its top drug Tecfidera Wednesday raised concerns over a potential generic threat from Mylan NV.Shares fell as much as 3.7% on Thursday, the most in two months, extending losses for a third day. Analysts held different views on the trial, with Evercore ISI Umer Raffat saying the hearing went better-than-expected for Biogen, while RBC analyst Brian Abrahams said Mylan seemed to make “a slightly stronger case.”“In totality, the arguments and judges’ reactions seemed to favor MYL incrementally,” …read more
Source:: Yahoo Finance
